Key result
Rheumatic valve surgery in Africa carries wide-ranging mortality up to ~23% and high reoperation rates.
Why the study?
Rheumatic heart disease is prevalent in Africa but advanced cardiac care including valve surgery is limited and clinical outcomes are variable.
What are the clinical outcomes and practices of valvular surgery for rheumatic heart disease in Africa?
What are the clinical outcomes and practices of valvular surgery for rheumatic heart disease in Africa?
Valve surgery for rheumatic heart disease in Africa shows promising clinical outcomes but is hindered by high variability in mortality and limited healthcare infrastructure.
High mortality variability signals need for standardized protocols and infrastructure investment in African RHD surgery; extends evidence base for region-specific quality initiatives.
BACKGROUND: Rheumatic heart disease is prevalent in Africa, but advanced cardiac care for the condition, which includes valve surgery, is limited. This study examined rheumatic heart disease surgical management and clinical outcomes in Africa. METHODS: This study followed the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. We conducted a comprehensive search of PubMed, Embase, Scopus, and Web of Science for keywords related to “rheumatic heart disease,” “valve surgery,” and “Africa.” Clinical studies published in African countries on valve surgery for rheumatic heart disease were included. RESULTS: The review included 17 studies from 10 countries. The prevalence of rheumatic heart disease had a female predominance (n = 1313/2367, 55.5%). Mitral valve procedures were universally reported. 7 studies highlighted moderate to severe valve disease severity. Clinical improvement was noted in two studies, with patients in NYHA Class I or II. Reoperation rates varied from 1.45% to 17%, and mortality rates from 3.85% to 22.67%. Hospital stays ranged from 5 to 16 days, and ICU stays from 2 to 3 days. Post-operative complications included thromboembolic disease, hypertrophic scars, infective endocarditis, left ventricular dysfunction, bioprosthetic valve dysfunction, arrhythmias, and neurological events such as stroke. CONCLUSION: Valve surgery for rheumatic heart disease in Africa shows promising clinical outcomes but faces challenges like outcome variability, postoperative complications, and limited infrastructure. Addressing diagnostic issues, enhancing follow-up care, and building healthcare capacity are essential for expanding effective surgical interventions and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Femi‐Lawal et al. (2025) conducted a review in Rheumatic heart disease (n=2,367). Valve surgery was evaluated on Clinical outcomes including mortality and reoperation rates. Valve surgery for rheumatic heart disease in Africa is associated with mortality rates ranging from 3.85% to 22.67% and reoperation rates from 1.45% to 17%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: